vs
Side-by-side financial comparison of SCYNEXIS INC (SCYX) and Zepp Health Corp (ZEPP). Click either name above to swap in a different company.
SCYNEXIS INC is the larger business by last-quarter revenue ($18.6M vs $10.5M, roughly 1.8× Zepp Health Corp). SCYNEXIS INC runs the higher net margin — 65.7% vs -2.1%, a 67.9% gap on every dollar of revenue. Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs -7.9%).
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
Zepp Health Corp is a global digital health and smart wearable technology company. It develops and sells fitness trackers, smartwatches, and AI-powered health monitoring tools, serving individual consumers, sports teams, and healthcare providers across Asia, North America, and Europe, with core focus on wellness tracking and remote health management solutions.
SCYX vs ZEPP — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.6M | $10.5M |
| Net Profit | $12.3M | $-223.0K |
| Gross Margin | — | 38.2% |
| Operating Margin | 56.3% | -1.2% |
| Net Margin | 65.7% | -2.1% |
| Revenue YoY | 1808.5% | — |
| Net Profit YoY | 376.5% | — |
| EPS (diluted) | $0.25 | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $18.6M | — | ||
| Q3 25 | $334.0K | $10.5M | ||
| Q2 25 | $1.4M | $8.2M | ||
| Q1 25 | $257.0K | $5.3M | ||
| Q4 24 | $977.0K | — | ||
| Q3 24 | $660.0K | $5.9M | ||
| Q2 24 | $736.0K | $5.6M | ||
| Q1 24 | $1.4M | $5.5M |
| Q4 25 | $12.3M | — | ||
| Q3 25 | $-8.6M | $-223.0K | ||
| Q2 25 | $-6.9M | $-1.1M | ||
| Q1 25 | $-5.4M | $-2.7M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-2.8M | $-1.8M | ||
| Q2 24 | $-14.5M | $-1.5M | ||
| Q1 24 | $411.0K | $-2.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | 38.2% | ||
| Q2 25 | — | 36.2% | ||
| Q1 25 | — | 37.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 40.6% | ||
| Q2 24 | — | 40.3% | ||
| Q1 24 | — | 36.8% |
| Q4 25 | 56.3% | — | ||
| Q3 25 | -2516.5% | -1.2% | ||
| Q2 25 | -701.0% | -10.3% | ||
| Q1 25 | -3350.2% | -47.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | -1563.6% | -29.5% | ||
| Q2 24 | -1255.0% | -24.3% | ||
| Q1 24 | -692.5% | -39.6% |
| Q4 25 | 65.7% | — | ||
| Q3 25 | -2572.2% | -2.1% | ||
| Q2 25 | -504.8% | -13.0% | ||
| Q1 25 | -2097.7% | -51.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | -425.5% | -31.2% | ||
| Q2 24 | -1964.4% | -26.7% | ||
| Q1 24 | 29.9% | -36.8% |
| Q4 25 | $0.25 | — | ||
| Q3 25 | $-0.17 | $-0.01 | ||
| Q2 25 | $-0.14 | $-0.07 | ||
| Q1 25 | $-0.11 | $-0.17 | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.06 | $-0.01 | ||
| Q2 24 | $-0.30 | $-0.01 | ||
| Q1 24 | $0.01 | $-0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $40.0M | $8.7M |
| Total DebtLower is stronger | — | $9.6M |
| Stockholders' EquityBook value | $49.4M | $31.2M |
| Total Assets | $59.0M | $80.9M |
| Debt / EquityLower = less leverage | — | 0.31× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $40.0M | — | ||
| Q3 25 | $37.9M | $8.7M | ||
| Q2 25 | $44.8M | $7.8M | ||
| Q1 25 | $40.6M | $10.7M | ||
| Q4 24 | $59.3M | — | ||
| Q3 24 | $68.8M | $16.4M | ||
| Q2 24 | $73.0M | $17.0M | ||
| Q1 24 | $80.2M | $17.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | $9.6M | ||
| Q2 25 | — | $9.7M | ||
| Q1 25 | — | $9.6M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $5.7M | ||
| Q2 24 | — | $7.3M | ||
| Q1 24 | — | $11.2M |
| Q4 25 | $49.4M | — | ||
| Q3 25 | $36.4M | $31.2M | ||
| Q2 25 | $44.5M | $31.1M | ||
| Q1 25 | $50.5M | — | ||
| Q4 24 | $55.1M | — | ||
| Q3 24 | $58.5M | — | ||
| Q2 24 | $60.4M | $44.6M | ||
| Q1 24 | $74.1M | — |
| Q4 25 | $59.0M | — | ||
| Q3 25 | $51.1M | $80.9M | ||
| Q2 25 | $60.7M | $75.8M | ||
| Q1 25 | $67.9M | $71.6M | ||
| Q4 24 | $90.6M | — | ||
| Q3 24 | $99.0M | $81.3M | ||
| Q2 24 | $107.8M | $79.7M | ||
| Q1 24 | $118.3M | $80.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.31× | ||
| Q2 25 | — | 0.31× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.16× | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $18.4M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 1.50× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.4M | — | ||
| Q3 25 | $-8.7M | — | ||
| Q2 25 | $-7.5M | — | ||
| Q1 25 | $-7.5M | — | ||
| Q4 24 | $-24.0M | — | ||
| Q3 24 | $765.0K | — | ||
| Q2 24 | $-10.9M | — | ||
| Q1 24 | $-4.0M | — |
| Q4 25 | 1.50× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -9.75× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
ZEPP
Segment breakdown not available.
